Three-Dose Schedule Of Meningococcal Serogroup B Vaccine Offers No Additional Immunologic Benefit When Compared With Two-Dose Schedule, Study Finds

Infectious Disease Advisor (12/27, Basilio) reported, “A 3-dose schedule of the meningococcal serogroup B (MenB) vaccine (4CMenB) provides no additional immunologic benefit when compared with a 2-dose schedule, according to results of a study.” Investigators came to this conclusion after conducting “a phase 3, randomized, controlled, observer-blinded study...that was conducted from August 2020 through September 2022 across 114 centers in 7 countries.” The findings were published in Open Forum Infectious Diseases.